{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:08:00Z","timestamp":1790636880764,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["674909"],"award-info":[{"award-number":["674909"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejps.2020.105617","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T10:47:22Z","timestamp":1603536442000},"page":"105617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-0823","authenticated-orcid":false,"given":"Angela","family":"Effinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M.","family":"O'Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105617_bib0001","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ejpb.2014.08.011","article-title":"Prediction of oral absorption of cinnarizine\u2013a highly supersaturating poorly soluble weak base with borderline permeability","volume":"88","author":"Berlin","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1386207319666160502123917","article-title":"Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery","volume":"19","author":"Bharate","year":"2016","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.ejps.2020.105617_bib0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.2009.04039.x","article-title":"Mechanisms of diarrhea in inflammatory bowel diseases","volume":"1165","author":"Binder","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0004","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/jps.1076","article-title":"Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model","volume":"90","author":"Bjorkman","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ejps.2020.105617_bib0006","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.2042-7158.2012.01538.x","article-title":"A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution","volume":"64","author":"Darwich","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0007","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1038\/psp.2013.23","article-title":"Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine","volume":"2","author":"Darwich","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0008","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbmt.2008.12.001","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease","volume":"15","author":"Dilger","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejps.2020.105617_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2003.10","article-title":"Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects","volume":"73","author":"Dresser","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.ejps.2020.105617_bib0010","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0928-0987(00)00181-0","article-title":"In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs","volume":"11","author":"Dressman","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0011","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105617_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00613465","article-title":"Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man","volume":"29","author":"Edsb\u00e4cker","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0013","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules","volume":"17","author":"Edsbacker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2036.2003.01431.x","article-title":"Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole","volume":"17","author":"Edsbacker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/00042737-200212000-00012","article-title":"Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules","volume":"14","author":"Edsbacker","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejps.2020.105617_bib0016","first-page":"9","article-title":"Budesonide capsules: Scientific basis","volume":"36","author":"Edsbacker","year":"2000","journal-title":"Drug Today"},{"key":"10.1016\/j.ejps.2020.105617_bib0017","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jphp.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption - implications for formulation design - a PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0018","article-title":"Gastrointestinal diseases and their impact on drug solubility: Crohn's disease","volume":"152","author":"Effinger","year":"2020","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejps.2020.105617_bib0019","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1023\/A:1026664105112","article-title":"Inflammation Does Not Decrease Intraluminal pH in Chronic Inflammatory Bowel Disease","volume":"44","author":"Ewe","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0378-4347(94)00473-I","article-title":"High-performance liquid chromatographic method for the determination of budesonide in bronchoalveolar lavage of asthmatic patients","volume":"664","author":"Faouzi","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.ejps.2020.105617_bib0021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","article-title":"Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn's Disease Patients with Different Disease Activity Using Video Capsule Endoscopy","volume":"18","author":"Fischer","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2020.105617_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejpb.2009.04.012","article-title":"A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations","volume":"73","author":"Fotaki","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0023","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejps.2005.07.004","article-title":"Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration","volume":"26","author":"Fotaki","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejps.2004.10.003","article-title":"In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis","volume":"24","author":"Fotaki","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1874126601004020002","article-title":"Biorelevant dissolution methods and their applications in in vitro in vivo correlations for oral formulations","volume":"4","author":"Fotaki","year":"2010","journal-title":"The Open Drug Delivery Journal"},{"key":"10.1016\/j.ejps.2020.105617_bib0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2133\/dmpk.25.28","article-title":"Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions","volume":"25","author":"Galetin","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105617_bib0027","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00054725-200002000-00002","article-title":"A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998","volume":"6","author":"Gasche","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejps.2020.105617_bib0028","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/bja\/71.6.827","article-title":"Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil","volume":"71","author":"Gesink-van der Veer","year":"1993","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ejps.2020.105617_bib0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2018.03.002","article-title":"Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water","volume":"127","author":"Grimm","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/00365521.2012.743584","article-title":"Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics","volume":"48","author":"Haapamaki","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejps.2020.105617_bib0031","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bcp.12502","article-title":"Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans","volume":"79","author":"Hohmann","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0032","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/cpt.750","article-title":"PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters","volume":"103","author":"Hsueh","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0033","first-page":"39","article-title":"Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis","volume":"7","author":"Iborra","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.ejps.2020.105617_bib0034","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejps.2020.105617_bib0035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0889-8553(21)00213-2","article-title":"Nutritional considerations in inflammatory bowel diseases","volume":"24","author":"Kelly","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ejps.2020.105617_bib0036","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/0016-5085(90)90500-Z","article-title":"The myth of serum albumin as a measure of nutritional status","volume":"99","author":"Klein","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2020.105617_bib0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/1319-3767.182455","article-title":"Implementation of the simple endoscopic activity score in crohn's disease","volume":"22","author":"Koutroumpakis","year":"2016","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.ejps.2020.105617_bib0038","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","article-title":"Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis","volume":"56","author":"Lee","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105617_bib0039","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00365521.1976.12097178","article-title":"Bile acid metabolism and plasma protein turnover in Crohn's disease","volume":"11","author":"Lenz","year":"1976","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.ejps.2020.105617_bib0040","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00054725-200407002-00002","article-title":"Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease","volume":"10","author":"Lichtenstein","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejps.2020.105617_bib0041","first-page":"1261","article-title":"Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data","volume":"36","author":"Lu","year":"2008","journal-title":"III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos"},{"key":"10.1016\/j.ejps.2020.105617_bib0042","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","article-title":"Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease","volume":"15","author":"Lundin","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0043","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2036.2003.01386.x","article-title":"Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease","volume":"17","author":"Lundin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0044","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.03.009","article-title":"In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media","volume":"93","author":"Markopoulos","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0045","first-page":"219","article-title":"Accumulation of mesalazine pills in the medium ileum in a patient with Crohn s disease","volume":"109","author":"Martinez Huertas","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.ejps.2020.105617_bib0046","series-title":"Henry's Clinical Diagnosis and Management by Laboratory Methods","author":"McPherson","year":"2011"},{"key":"10.1016\/j.ejps.2020.105617_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40360-018-0221-6","article-title":"Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients","volume":"19","author":"Molanaei","year":"2018","journal-title":"BMC Pharmacol and Toxicol"},{"key":"10.1016\/j.ejps.2020.105617_bib0048","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0049","first-page":"A977","article-title":"Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease","volume":"110","author":"Naber","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2020.105617_bib0050","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0300060513476588","article-title":"Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers","volume":"41","author":"Nicholls","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ejps.2020.105617_bib0051","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/gut.23.9.751","article-title":"Bile acid absorption kinetics in Crohn's disease on elemental diet after oral administration of a stable-isotope tracer with chenodeoxycholic-11, 12-d2 acid","volume":"23","author":"Nishida","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2020.105617_bib0052","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.crohns.2014.03.003","article-title":"Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease","volume":"8","author":"Niv","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ejps.2020.105617_bib0053","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2036.1998.00358.x","article-title":"Gastrointestinal pH profiles in patients with inflammatory bowel disease","volume":"12","author":"Press","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0054","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","article-title":"Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients","volume":"56","author":"Radke","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105617_bib0055","unstructured":"Rohatgi, A., 2018. WebPlotDigitizer, 4.1 ed, San Francisco, California, USA."},{"key":"10.1016\/j.ejps.2020.105617_bib0056","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gut.20.12.1072","article-title":"Bile acid studies in patients with Crohn's colitis","volume":"20","author":"Rutgeerts","year":"1979","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2020.105617_bib0057","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","article-title":"Drug\u2212disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity","volume":"72","author":"Sanaee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0058","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/gut.23.4.326","article-title":"Comparison of the composition of faecal fluid in Crohn's disease and ulcerative colitis","volume":"23","author":"Schilli","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2020.105617_bib0059","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1067\/mcp.2000.106895","article-title":"Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration","volume":"68","author":"Seidegard","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0060","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejps.2008.07.005","article-title":"Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole","volume":"35","author":"Seidegard","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0061","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ejps.2012.04.005","article-title":"Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum","volume":"46","author":"Seidegard","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0062","first-page":"461","article-title":"Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations","volume":"64","author":"Seidegard","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2020.105617_bib0063","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mcp.2000.105762","article-title":"Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol","volume":"67","author":"Seidegard","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0064","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455008","article-title":"Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease","volume":"95","author":"Shah","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.ejps.2020.105617_bib0065","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/mp500834v","article-title":"Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data","volume":"12","author":"Sj\u00f6gren","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0066","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejps.2004.11.007","article-title":"In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media","volume":"24","author":"Sunesen","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0067","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0091-6749(99)70059-X","article-title":"Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid","volume":"104","author":"Szefler","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejps.2020.105617_bib0068","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejps.2013.10.001","article-title":"Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans","volume":"57","author":"Tannergren","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0069","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105617_bib0070","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3109\/00365529209011182","article-title":"Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease","volume":"27","author":"Tromm","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejps.2020.105617_bib0071","unstructured":"US Food and Drug Administration, 2000. New Drug Application Entocort (21-324): Clinical Pharmacology and Biopharmaceutics Review."},{"key":"10.1016\/j.ejps.2020.105617_bib0072","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0148607107031004311","article-title":"Nutrition assessment of patients with inflammatory bowel disease","volume":"31","author":"Vagianos","year":"2007","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.ejps.2020.105617_bib0073","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/gut.18.9.730","article-title":"Bile acid studies in uncomplicated Crohn's disease","volume":"18","author":"Vantrappen","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2020.105617_bib0074","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/BF01536987","article-title":"Organic anions and the diarrhea of inflammatory bowel disease","volume":"33","author":"Vernia","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ejps.2020.105617_bib0075","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","article-title":"Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility","volume":"27","author":"Vertzoni","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejps.2020.105617_bib0076","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2005.03.002","article-title":"Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds","volume":"60","author":"Vertzoni","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejps.2020.105617_bib0077","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/MIB.0000000000001062","article-title":"CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease","volume":"23","author":"Wilson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejps.2020.105617_bib0078","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00054725-200409000-00018","article-title":"Impaired gastric acid and pancreatic enzyme secretion in patients with Crohn's disease may be a consequenece of a poor nutritional state","volume":"10","author":"Winter","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ejps.2020.105617_bib0079","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0091270004273320","article-title":"CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations","volume":"45","author":"Xie","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2020.105617_bib0080","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1215035","article-title":"Body Composition in Crohn's Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration","volume":"2017","author":"Yadav","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejps.2020.105617_bib0081","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ejps.2020.105617_bib0082","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030405X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030405X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:11:13Z","timestamp":1769886673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872030405X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":82,"alternative-id":["S092809872030405X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105617","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105617"}}